Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention

S. M. Reed  
*University of Kentucky*

M. Furr  
*Oklahoma State University*

Daniel K. Howe  
*University of Kentucky, daniel.howe@uky.edu*

A. L. Johnson  
*University of Pennsylvania*

R. J. MacKay  
*University of Florida*

Follow this and additional works at: [https://uknowledge.uky.edu/gluck_facpub](https://uknowledge.uky.edu/gluck_facpub)

See next page for additional authors

Part of the [Large or Food Animal and Equine Medicine Commons](https://uknowledge.uky.edu/largeorfoodanimal) and the [Veterinary Preventive Medicine, Epidemiology, and Public Health Commons](https://uknowledge.uky.edu/veterinarypreventive)

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation

Reed, S. M.; Furr, M.; Howe, Daniel K.; Johnson, A. L.; MacKay, R. J.; Morrow, J. K.; Pusterla, N.; and Witonsky, S., "Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention" (2016). *Veterinary Science Faculty Publications*. 33.  
[https://uknowledge.uky.edu/gluck_facpub/33](https://uknowledge.uky.edu/gluck_facpub/33)

This Article is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Veterinary Science Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Authors
S. M. Reed, M. Furr, Daniel K. Howe, A. L. Johnson, R. J. MacKay, J. K. Morrow, N. Pusterla, and S. Witonsky

Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention

Notes/Citation Information
Published in Journal of Veterinary Internal Medicine, v. 30, issue 2, p. 491-502.

Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Digital Object Identifier (DOI)
https://doi.org/10.1111/jvim.13834

This article is available at UKnowledge: https://uknowledge.uky.edu/gluck_facpub/33
Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention

S.M. Reed, M. Furr, D.K. Howe, A.L. Johnson, R.J. MacKay, J.K. Morrow, N. Pusterla, and S. Witonsky

Equine protozoal myeloencephalitis (EPM) remains an important neurologic disease of horses. There are no pathognomonic clinical signs for the disease. Affected horses can have focal or multifocal central nervous system (CNS) disease. EPM can be difficult to diagnose ante-mortem. It is caused by either of 2 parasites, Sarcocystis neurona and Neospora hughesi, with much less known about N. hughesi. Although risk factors such as transport stress and breed and age correlations have been identified, biologic factors such as genetic predispositions of individual animals, and parasite-specific factors such as strain differences in virulence, remain largely undetermined. This consensus statement update presents current published knowledge of the parasite biology, host immune response, disease pathogenesis, epidemiology, and risk factors. Importantly, the statement provides recommendations for EPM diagnosis, treatment, and prevention.

Key words: Encephalitis; Equine myeloencephalopathy; Equine neurologic; Equine protozoal disease; Myelitis; Neospora hughesi; Sarcocystis neurona.
1976. It is now well established that EPM can be caused by either Sarcocystis neurona or Neospora hughesi, although the majority of cases are because of infection with S. neurona. Sarcocystis neurona has a 2-host life cycle that alternates between the definitive host, and any of multiple mammal intermediate hosts. The opossum Didelphis virginiana is the definitive host for S. neurona in North America. As well, South American opossums can act as definitive hosts for S. neurona in the southern hemisphere. Sexual reproduction by the parasite in the intestinal epithelium of the infected opossum results in the production of sporozoite-containing sporocysts that are passed in the feces. The sporozoites are infectious for the intermediate hosts, which include skunks, raccoons, armadillos, and cats. S. neurona forms latent sarcocysts in the muscle tissue of the intermediate host; sarcocyst-laden muscle is the source of infection for the opossum. Opossums are commonly infected with S. neurona and can generate significant contamination of the environment in locations which they frequent. Horses are infected with S. neurona by ingesting food or water that has been contaminated with feces from an infected opossum. Although S. neurona sarcocysts were described in 1 case of a 4-month-old foal with clinical signs of EPM, it is unlikely that horses are normal intermediate hosts that contribute to the parasite’s life cycle, as S. neurona has not been found typical in tissues of these animals and equine carcasses are seldom accessible to opossums. Importantly, S. neurona is not transmitted horizontally between horses, nor can it be transmitted to horses from nonequine intermediate hosts. Antibodies against S. neurona in foals before suckling have been reported, but vertical transmission of this parasite in horses is probably uncommon. Thus, opossums are the major source of S. neurona infection for horses. The exact mechanisms by which S. neurona enters the CNS are not known, but are thought to involve either infection of endothelial cells or leukocytes.

The complete life cycle of N. hughesi is unknown, so all mode(s) of transmission of this parasite to horses remain poorly understood. Canids are a definitive host for the related species Neospora caninum, but it has not been established that dogs or wild canids are a definitive host for N. hughesi. Vertical transmission of N. caninum is very efficient in cattle, and several recent studies indicate that N. hughesi can be transmitted transplacentally in horses. All horses are believed to be susceptible to EPM, but it is clear that not all horses that are infected with S. neurona or N. hughesi will develop disease. Studies in both mannered horses experimentally infected with S. neurona have demonstrated a critical role for the immune response in preventing disease. Additionally, some EPM-affected horses have demonstrated altered immune responses, some of which are antigen-specific. As is clear from the finding that not all horses have demonstrated decreased immune responses with the methodology employed, the mechanisms involving the development of disease remain poorly understood.

It is unclear what influences the progression to severe neurologic disease. Factors such as variations in protozoal inoculum and stress-induced immune suppression have been implicated in the occurrence of EPM. However, efforts to increase stress (ie, by additional transport of infected horses) and treatment with immunosuppressive steroids did not cause a concomitant increase in disease severity. Genetic variation has been observed among the strains of S. neurona that have been analyzed and there is some evidence that specific parasite genotypes may be particularly virulent in marine mammals. However, such an association was not apparent in isolates from horses suffering from EPM.

Epidemiology and Risk Factors

A survey using postmortem data from 10 diagnostic centers throughout the United States and Canada found that a majority of EPM cases (61.8%) occurred in horses that were 4 years old or less, whereas only 19.8% of the EPM cases reviewed were in horses 8 years or older. Thoroughbreds, Standardbreds, and Quarter Horses were most commonly observed, but no sex or seasonal bias could be established. A smaller retrospective study of 82 horses with histologic lesions compatible with EPM suggested that EPM risk was highest among male Standardbreds. The mean age of affected horses was 3.6 ± 2.8 years, similar to that found by Fayer et al. The seroprevalence of S. neurona in horses from the United States has varied widely, ranging from as low as 15% to a high of 89%, depending on geographic location. Seroprevalences of 35.6% and 35.5% have been observed in horses in Brazil and Argentina, respectively, thus indicating that this parasite commonly infects horses in South America.

In general, the seroprevalence of N. hughesi is low in horses. Serum antibodies against N. hughesi have been reported in more than 10% of horses in some geographic regions, whereas other studies found antibodies against N. hughesi in much lower proportions of horses (ie, <3%). Some of the variation may be because of geographic differences, but studies that used Western blot to confirm serologic results have suggested that seroprevalence to N. hughesi is commonly overestimated.

A survey reported in 2001 by the National Animal Health Monitoring System (NAHMS) estimated that the annual incidence of EPM in horses 6 months of age or older was 14 ± 6 cases per 10,000 horses. While it is now known that N. hughesi can cause neurologic disease in horses, the proportion of EPM cases attributable to this parasite species remains uncertain. EPM usually occurs sporadically and seldom involves more than 1 horse on a farm, although clusters of cases can occur. A retrospective study found that young horses (1–5 years) and older horses (>13 years) had a higher risk of developing EPM, as observed previously. EPM occurred the least in the winter, with
the risk 3 times higher in spring and summer and 6 times higher in the fall. On a given premise, the presence of opossums (2.5-fold), previous diagnosis of EPM (2.5-fold), and the presence of wooded areas (2-fold) were also associated with increased risk of EPM. The likelihood of EPM was reduced by one third when wildlife was prevented access to feed and by one-half when a creek or river was present as a water source. Immune suppression because of stress or advanced age might predispose a horse to development of EPM. Stressful events such as heavy exercise, transport, injury, surgery, or parturition have all been found to increase the risk of EPM. Racehorses and show horses had a higher risk of developing EPM compared to breeding horses. Not surprisingly, horses with EPM that were treated with an anticoccidial drug were 10 times more likely to improve than untreated horses.

Clinical Signs

Clinical signs of EPM vary from acute to chronic with insidious onset of focal or multifocal signs of neurologic disease involving the brain, brainstem, or spinal cord. Initial signs might include dysphagia, evidence of abnormal upper airway function, unusual or atypical lameness, or even seizures. Severely affected horses might have difficulty standing, walking, or swallowing and the disease can progress very rapidly. Occasionally, the clinical signs stabilize, only to relapse days or weeks later.

The variability of clinical signs is because of infection of both white and gray matter at multiple sites in the CNS. Signs of gray matter involvement include focal muscle atrophy and severe muscle weakness, whereas damage to white matter frequently results in ataxia and weakness in limbs caudal to the site of infection. Early signs of EPM such as stumbling and frequent interference between limbs can be confused with lameness. Horses affected with EPM commonly exhibit a gradual progression in severity and range of clinical signs. In some cases, however, a gradual onset can give way to a sudden exacerbation in the severity of clinical illness, resulting in recumbency.

The vital signs in affected horses are usually normal and animals appear bright and alert. Some horses with EPM appear thin and mildly obtunded. Neurologic examination often reveals asymmetric ataxia, weakness, and spasticity involving all 4 limbs. Areas of hyporeflexia, hypalgesia, or complete sensory loss are occasionally present. The most common signs of brain/brainstem disease include obtundation, head tilt, facial nerve paralysis, and difficulty in swallowing, although signs are not necessarily limited to these areas.

Recommendations for EPM Diagnosis

Definitive diagnosis of EPM requires postmortem confirmation of protozoal infection of the CNS (see below). For highest accuracy in antemortem diagnosis, the following steps are recommended. (1) The presence of clinical signs consistent with EPM should be confirmed by conducting a thorough neurologic examination. (2) Other potential causes should be ruled out using available tools (eg, cervical radiography). (3) Immunodiagnostic testing of serum and CSF should be conducted to confirm intrathecal antibody production against S. neurona or N. hughesi. The ratio of antibody in serum to CSF will reveal intrathecal antibodies in most cases of EPM. The Goldman-Witmer coefficient (C-value) or the antigen-specific antibody index (AI) should be applied for cases that have ELISA titer results that are equivocal (ie, the serum:CSF ratio equals the cut-off) or when a condition that compromises the blood–brain barrier is suspected. The SnSAG2, 4/3 ELISA serum:CSF titer ratio and NhSAG1 ELISA serum:CSF titer ratio are the only tests currently offered commercially that provide information regarding intrathecal antibody production based on serum and CSF titers. The commercially available S. neurona and N. hughesi IFATs do determine antibody titers in both the serum and CSF, but the laboratory does not calculate ratios at this time.

Basis for Recommendations

In horses with clinical signs consistent with CNS disease, EPM should be considered as a differential. Affected horses should initially have a thorough neurologic examination to identify abnormalities, and localize the lesion(s), which will allow one to further refine the differentials. This, combined with the use of appropriate diagnostic tests, will assist in diagnosing EPM and ruling out other causes. Some of the most consistent/classic clinical signs include asymmetric gait and focal muscle atrophy. When these signs are present, EPM should be considered as a top differential diagnosis. EPM-affected horses are not painful, and rarely febrile, unless comorbidities exist.

Differential Diagnoses

Almost all neurologic diseases in horses can have clinical signs that are also present in EPM-affected horses. A thorough neurologic examination and diagnostic tests are needed to distinguish between EPM and other differentials. Some diseases have other more consistent/classic signs that allow one to rule them in or out. With cervical vertebral stenotic myelopathy (CVSM), signs usually are symmetric and, typically, the pelvic limbs are more severely affected than the thoracic limbs. Focal muscle atrophy is not common. Trauma should also be considered as a differential cause of spinal cord damage at any level, potentially causing abnormal neurologic signs in 1 to all limbs.

In horses where there is a history of respiratory disease or an outbreak of abortion, EHV-1-associated neurologic disease should be considered as a more likely differential. EHV-1-affected horses may be febrile shortly before or at the onset of neurologic signs. In the EHV-1-affected horses, neurologic signs typically manifest as symmetric, with primary pelvic limb weakness and ataxia, bladder distention, usually without incontinence, and, more rarely, perineal hypalgesia, tail paralysis.
sis, fecal retention and in some cases incontinence as well. Some affected horses show rapidly progressing signs of ataxia and can sometimes have cranial nerve deficits, often involving cranial nerves VII to XII. In other cases, cerebral signs occur.

Another disease which should be considered as a differential diagnosis is equine motor neuron disease (EMND). Affected horses with early stages of disease typically have severe limb weakness with muscle fasciculations and tremors. Horses with chronic EMND can have widespread, profound, muscle atrophy.

Other differentials of spinal cord disease that can result in similar clinical signs include extradural and spinal cord tumors, epidural abscess, migrating metazoan parasites, rabies, West Nile viral encephalomyelitis, equine degenerative myeloencephalopathy/neuroaxonal dystrophy, lead poisoning, creeping indigo toxicity, Lyme neuro-borreliosis, vascular malformations, and discospondylopathies. If affected horses have signs of cranial nerve or brain involvement, EPM should be considered as a differential. Other rule-outs include viral encephalomyelitides, neoplasms, head trauma, brain abscess, migrating parasitic granulomas, temporohyoid osteoarthropathy, polyneuritis equi, cholesterol granuloma, metabolic derangement, and hepatoencephalopathy.

**Postmortem Diagnosis**

Confirmation of EPM on postmortem examination is based on demonstration of protozoa in CNS lesions, although the diagnosis frequently is made presumptively even when parasites are not detected if the characteristic inflammatory changes are found. In 2 reported series, organisms were seen in H&E sections of CNS tissue in 10 to 36% of suspected cases. Sensitivity was increased from 20 to 51% by immunohistochemical staining with antibody against *S. neurona*. Although it has not been demonstrated experimentally, the use of PCR to detect parasites in CNS tissues might aid postmortem diagnosis of EPM. There is decreased likelihood of finding parasites histologically in tissues from affected EPM horses that have been treated with antiprotozoal drugs.

All commonly used tests are based on detection of antiprotozoal antibodies in serum, CSF, or both. As EPM occurs only in a small proportion of horses infected with *S. neurona*, testing for serum antibodies against *S. neurona* has minimal diagnostic value unless the serologic results are negative (low positive predictive value but high negative predictive value). However, detection of serum antibodies against *N. hughesi* in a neurologic horse has a higher positive predictive value because of a much slower course of disease. A negative serum test usually indicates that the horse has not been infected and alternative diagnoses should be pursued or that the EPM-suspect horse resides in a geographic area of low exposure to the infecting parasite. However, a recently infected horse might display clinical signs before seroconversion, and repeated serologic testing in 10–14 days is indicated for horses with recent development of compatible clinical signs. Detection of antibodies in the CSF is more informative, but alone is not a definitive indicator of EPM as there is passive transfer across the BBB. Logically, horses with higher serum titers are more likely to have detectable antibody levels in CSF in both of these circumstances.

**Use of quantitative assays to detect intrathecal antibody production, indicating active parasite infection in the CNS, provides an alternative approach for EPM diagnosis. The Goldman-Witmer coefficient (C-value) and the antigen-specific antibody index (AI) are tests of proportionality that assess whether the amount of pathogen-specific antibody in the CSF is greater than should be present from normal passive transfer across the BBB. These methods have been used in various studies designed to diagnose CNS infections caused by a variety of pathogens, including the apicomplexan *T. gondii*. The value of these tests for EPM diagnosis was demonstrated initially with a sample set of 29 clinical cases. This study also showed that minor blood contamination of CSF samples resulting in up to 5000 white blood cells per μL will not confound the assay results. Subsequently, 2 additional studies examining a more extensive collection of horses with neurologic disease showed that a simple serum:CSF antibody titer ratio was sufficient in many cases for an accurate diagnosis of EPM caused by *S. neurona*. Although use of a serum:CSF titer ratio should be equally effective for diagnosis of EPM caused by *N. hughesi*, an optimal serum:CSF titer ratio cut-off needs to be established.

**Available tests for EPM caused by *S. neurona***

Numerous serologic tests have become available during the past 2 decades to aid in the diagnosis of EPM caused by *S. neurona*, including Western blot (WB), indirect fluorescent antibody test (IFAT), and surface antigen (SAG) enzyme-linked immunosorbent assays (ELISAs). Descriptions of testing options and reported test performance are shown in Table 1. All tests can be performed on serum or CSF, and none is
considered a gold standard. The WB, the first immunodiagnostic test described for EPM, is a qualitative test for antibodies against merozoite lysate. Its use has largely been supplanted by more quantitative tests, and positive WB results have limited diagnostic utility. However, negative WB results retain a high negative predictive value. The IFAT is a quantitative (end-point titer) test for antibodies against culture-derived whole parasite protein has been described. However, this antigen is not expressed by all strains of *S. neurona*, thereby reducing its utility for serologic detection and EPM diagnosis. An ELISA combining SnSAG1 with 2 additional SnSAGs (SnSAG5 and SnSAG6) is currently offered. However, no published reports describe validation of this assay, so it is unclear whether the test reliably detects antibodies to *S. neurona*.

Several studies have directly compared different tests for EPM (caused by *S. neurona* infection); these publications and 3 unpublished studies presented at ACVIM EPM Society SIGs are detailed in Table 2. Although none of the studies examined all of the currently available tests, and the types of samples utilized were variable, some general conclusions are evident. Testing serum alone yielded less accurate results than testing CSF alone or a serum:CSF titer ratio, generally because of low specificity. One notable exception was the SnSAG1 ELISA, which showed poor sensitivity. Poor to fair test agreement was observed; samples that were split and submitted to multiple labs often had discrepant results. Three of the 6 comparison studies evaluated the SnSAG2/4/3 ELISA serum:CSF titer ratio; in all 3 studies this test demonstrated the highest

### Table 1. Performance of commercially available immunologic tests for antibodies against *Sarcocystis neurona*.

| Test | Laboratory | Interpretation | Sample    | Sensitivity (%) | Specificity (%) |
|------|------------|----------------|-----------|----------------|----------------|
| WB   | EDS        | Band pattern read and interpreted visually (subjective) | Serum     | 89<sup>93</sup>, 80<sup>82</sup>, 89<sup>93</sup> | 71<sup>93</sup>, 38<sup>82</sup>, 87<sup>93</sup> |
|      | UC Davis   | Results usually reported as negative, weak positive, low positive, or positive | CSF       | 89<sup>93</sup>, 87<sup>82</sup> | 89<sup>93</sup>, 44<sup>82</sup> |
|      | IDEXX      | Similar to standard WB (above) | Serum     | 100<sup>90</sup>, 89<sup>93</sup> | 98<sup>90</sup>, 60<sup>93</sup> ("n.b., negative cases not from North America) |
| mWB  | Michigan State | Serum positive at ≥1:80 has ≥55% probability of EPM | Serum     | 89<sup>93</sup>, 83<sup>84</sup>, 94<sup>90</sup>, 59<sup>71</sup> | 100<sup>93</sup>, 97<sup>94</sup>, 85<sup>89</sup>, 71<sup>71</sup> |
|      |            | Serum negative at ≤1:40 has ≤33% probability of EPM | CSF       | 100<sup>94</sup>, 92<sup>99</sup>, 65<sup>71</sup> | 99<sup>94</sup>, 90<sup>99</sup>, 98<sup>71</sup> |
|      |            | CSF positive at ≥1:5 has 92% probability of EPM | Serum:CSF titer ratio | 65<sup>71</sup> | 98<sup>71</sup> |
| IFAT | UC Davis   | Serum positive at ≥1:16 but recommended cutoff ≥1:32 | Serum     | 68<sup>88</sup>, 13<sup>89</sup> | 71<sup>88</sup>, 97<sup>89</sup> |
|      |            | Serum positive for exposure at ≥1:250 | Serum     | 30–86 (depending on cutoff) | 37–88 (depending on cutoff) |
|      |            | CSF correlates well with EPM if ≥1:40 | CSF       | 77–96 (depending on cutoff) | 58–96 (depending on cutoff) |
|      |            | Serum:CSF titer ratio very predictive of EPM if ≤100 | Serum:CSF titer ratio or 93 (cutoff ≤100) | 86 (cutoff ≤50) | 96 (cutoff ≤50) or 83 (cutoff ≤100) |
| SAG1  | Antech     | Serum positive at ≥1:8, indicating infection | Serum     | N/A | N/A |
| SAG2, 4/3 ELISA | EDS | Serum positive for exposure at ≥1:250 | Serum     | 30–86 (depending on cutoff) | 37–88 (depending on cutoff) |
|      |            | Serum positive at ≥1:16 but recommended cutoff ≥1:32 | Serum     | 68<sup>88</sup>, 13<sup>89</sup> | 71<sup>88</sup>, 97<sup>89</sup> |

WB, Western blot; mWB, modified Western blot; IFAT, indirect fluorescent antibody test; SAG, surface antigen; ELISA, enzyme-linked immunosorbent assay; EDS, Equine Diagnostic Solutions (Lexington, KY); UC Davis, University of California at Davis; EPM, equine protozoal myeloencephalitis; CSF, cerebrospinal fluid.

<sup>a</sup>Based on pretest probability of 10%; see reference 85.
Table 2. Test comparisons related to EPM caused by *Sarcocystis neurona*

| References        | Tests (and samples) compared | Sample origin | Results | Author conclusions |
|-------------------|-----------------------------|---------------|---------|--------------------|
| Duarte et al. (2003) | WB (serum) • mWB (serum) • IFAT (serum) | Necropsy cases (9 positive, 39 negative) | Similar Se (89%) for all 3 | IFAT accuracy was better than WB tests. |
| (2007)            | WB (serum) • mWB (serum) • IFAT (serum) • SAG1 ELISA (serum) | Experimental cases (1. *Sarcocystis neurona* positive, 1 *S. fayeri* positive, 2 negative) | Variable for each case; limited agreement between tests | WB and IFAT were most accurate, though IFAT was cross-reactive with *S. fayeri*. mWB tended to have false-positive results, whereas SAG1 ELISA tended to have false-negative results. |
| Johnson et al. (2010) | IFAT (serum, CSF) • SAG1 ELISA (serum) | Necropsy cases (9 positive, 17 negative) | Marked difference in Se (IFAT serum 94%, IFAT CSF 92%, SAG1 ELISA serum 13%) | Low Se limited the usefulness of the SAG1 ELISA. |
| (2010)            | WB (CSF) • IFAT (serum) • SAG1 ELISA (serum) • SAG2, 4/3 ELISA (serum:CSF ratio) | Necropsy cases (7 positive, 5 negative) | Comparable Sp (IFAT serum 85%, IFAT CSF 90%, SAG1 ELISA serum 97%) | SAG2, 4/3 ELISA serum:CSF ratio was the most accurate. |
| (2012)            | IFAT (CSF) • SAG2, 4/3 ELISA (serum:CSF ratio) | Necropsy cases (6 positive, 17 negative) | Variable Se (SAG2, 4/3 ELISA 90%, WB 90%, IFAT 70%, SAG1 ELISA 55%) | IFAT advantages include testing for *N. hughesi* and use as serum stand-alone test. (*n.b., SAG2, 4/3 ELISA serum:CSF ratio had higher overall accuracy.*) |
| (2013)            | IFAT (serum, CSF, serum:CSF ratio) • SAG2, 4/3 ELISA (serum, CSF, serum:CSF ratio) | Necropsy cases (11 positive, 28 negative) | SAG2, 4/3 ELISA serum:CSF ratio was most accurate (97%) | Serum testing alone was least accurate; more accurate methods should be used. SAG2, 4/3 ELISA serum:CSF ratio was most accurate. |

ACVIM, American College of Veterinary Internal Medicine; EPM, equine protozoal myeloencephalitis; SIG, special interest group; WB, Western blot; mWB, modified Western blot; IFAT, indirect fluorescent antibody test; SAG, surface antigen; ELISA, enzyme-linked immunosorbent assay; Se, test sensitivity; Sp, test specificity; CSF, cerebrospinal fluid.

Overall accuracy as compared to the WB, IFAT, and SAG1 ELISA. However, the SAG1, 5, 6 ELISA has not yet been evaluated in any comparison study, so its performance is currently unknown.

**Available tests for EPM caused by *N. hughesi***

Two serologic assays are currently offered for measuring antibodies against *N. hughesi* in equine samples...
Table 3. Commercially available immunologic tests for antibodies against Neospora hughesi.

| Test       | Laboratory  | Interpretation                                                                 | Reported performance                         |
|------------|-------------|---------------------------------------------------------------------------------|----------------------------------------------|
| IFAT¹⁰⁰    | UC Davis    | • Serum positive at ≥1:320; negative at < 1:40                                  | • Serum Se 100%, Sp 100% at cutoff of 1:640   |
|            |             | • CSF positive at ≥1:5                                                           | • Serum Se 100%, Sp 71% at cutoff of 1:320    |
| ELISA⁶²    | EDS         | • Serum positive at ≥1:500                                                       | • Serum Se 94%, Sp 95% compared to WB detection antibodies (not EPM cases) |
|            |             | • CSF positive at ≥1:5                                                           |                                              |
|            |             | • Serum/CSF titer ratio provides most accurate EPM diagnosis                     |                                              |

IFAT, indirect fluorescent antibody test; ELISA, enzyme-linked immunosorbent assay; UC Davis, University of California at Davis; EDS, Equine Diagnostic Solutions (Lexington, KY); CSF, cerebrospinal fluid; EPM, equine protozoal myeloencephalitis; Se, sensitivity; Sp, specificity; WB, Western blot.

(Table 3). An ELISA based on the major parasite surface antigen NhSAG1⁶² is available from Equine Diagnostic Solutions, LLC, whereas an IFAT using whole N. hughesi tachyzoites is offered by the School of Veterinary Medicine, University of California-Davis, Veterinary Immunology Laboratory. Based on analysis of 1006 random equine samples, the NhSAG1 ELISA provides an estimated 94% sensitivity and 95% specificity for detecting antibodies against N. hughesi when compared to Western blot results. The N. hughesi IFAT sensitivity and specificity for detecting antibodies against N. hughesi was reported to be 100% and 71.4%, respectively, at a cut-off of 1:320.¹⁰⁰ These values were based on samples from 3 naturally infected, 7 experimentally infected, and 7 naïve horses. Of note, neither the N. hughesi IFAT nor the NhSAG1 ELISA have been fully validated for EPM diagnosis because of an inadequate number of samples from EPM cases caused by this parasite.

**Recommendations for EPM Treatment and Prevention**

For treatment of EPM, it is recommended that 1 of the FDA-approved anticoccidial drugs should be used to control infection. The current FDA-approved drugs are: a) Ponazuril (Marquis®; Merial, Inc., Duluth, Georgia, 30096, USA); b) Diclazuril (Protazil®; Merck Animal Health, Madison, NJ, 07940, USA); and c) Sulfadiazine/Pyrimethamine (eg, ReBalance®, PRN Pharmacal, Pensacola, Florida, 32514, USA). Additional medical and supportive treatment should be provided based on the severity of neurologic deficits and complications arising from them.

**Basis for Recommendations**

**Folate-Inhibiting Drugs**

A combination of sulfadiazine and pyrimethamine (SDZ/PYR) was 1 of the initial treatment for EPM. Sulfonamides and pyrimethamine act synergistically by interfering with folic acid metabolism and biosynthesis of purine and pyrimidine nucleotides necessary for the parasite’s survival.

A dosage regimen of PYR, 1 mg/kg PO q24 h, and SDZ, 20 mg/kg PO q24 h for up to 6 months was the earliest treatment for EPM. As dietary folate can interfere with the uptake of diaminopyrimidine drugs like PYR,¹⁰¹ hay should not be fed for 2 hours before or after treatment. PYR given PO to horses at 1 mg/kg/d achieves a concentration of approximately 0.02 to 0.10 µg/mL in the CSF 4–6 h after administration.¹⁰² These experimental horses were allowed free access to prairie hay, potentially reducing the bioavailability of the drug.¹⁰¹ One of the PK characteristics is that steady-state CSF concentrations of PYR can be obtained after 4–6 hours after a single PO administered dose at 1 mg/kg/d. Further, short half-lives of these compounds suggest that there will be large fluctuations between peak and trough concentrations in the CSF after single daily administration. Additionally, as PYR is concentrated in CNS tissue relative to plasma,¹⁰³ the concentration at the desired site of action might be >0.1 µg/mL. Mean peak CSF concentrations of sulfonamide after single or multiple dosing (22–44 mg/kg) have been reported to be approximately 2–8 µg/mL.¹⁰⁴ These drugs are available as an FDA-approved product (ReBalance®, PRN Pharmacal). Treatment efficacy determined by clinical improvement (2 or more improvement grades in the overall neurologic dysfunction) or reversion to a CSF negative status for S. neurona by immunoblot after 90 days of treatment showed success in 60–70% of treated horses.¹⁰⁵

The toxic effects of these drugs relate to the inhibition of folate synthesis and include bone marrow suppression, anorexia, urticaria, and self-limiting diarrhea.¹⁰²,¹⁰⁶ Typically, there is progressive mild anemia (PCV in the low 20s) over a 6-month treatment period; neutropenia and thrombocytopenia can be seen in some cases as well. Pyrimethamine is teratogenic, causing abortions in rats and congenital defects in
pups. In addition, mares treated with pyrimethamine in late pregnancy had a fatal syndrome observed in the foals. Of the 4 mares, 3 had been supplemented with folic acid. In other species, folic acid supplementation will not prevent PYR-induced toxicosis or can even exacerbate it. Therefore, the use of folic acid in EPM-affected horses treated with PYR cannot be justified.

**Benzeneacetonitrile Drugs**

Diclazuril and ponazuril, 2 members of the benzeneacetonitrile group of compounds, have been approved by the FDA for treatment of EPM (US FDA, Protazil™ antiprotozoal oral pellets. 1.56% diclazuril. Freedom of Information Summary; US FDA, Marquis™ antiprotozoal oral paste. 15% w/w ponazuril. Freedom of Information Summary). With demonstrated broad-spectrum anticoelid activity in many avian and mammalian species, these drugs are related to the herbicide atrazine and are thought to target the parasite's apicoplast organelle. The activity of benzeneacetonitrile compounds against *S. neurona* and *N. caninum* was initially shown in vitro. In horses, pharmacokinetic studies have established that therapeutic steady-state concentrations of both diclazuril and ponazuril are achieved by day 7 using labeled doses. Moreover, use of a loading dose of ponazuril at 15 mg/kg resulted in steady-state concentrations in blood and CSF by day 2. Furthermore, the concurrent administration of vegetable oil (1/2 cup) has shown to increase the bioavailability of the FDA-approved ponazuril product up to 15% (M. Furr, unpublished observations). A loading dose for the FDA-approved diclazuril product is not required, and use of vegetable oil does not increase its bioavailability (Hunyadi, unpublished observations). The FDA-approved benzeneacetonitrile compounds exhibited efficacy ranging from 62 to 67% based on a neurologic examination. The activity of benzeneacetonitrile compounds against *S. neurona* and *N. caninum* was initially shown in vitro. In horses, pharmacokinetic studies have established that therapeutic steady-state concentrations of both diclazuril and ponazuril are achieved by day 7 using labeled doses. Moreover, use of a loading dose of ponazuril at 15 mg/kg resulted in steady-state concentrations in blood and CSF by day 2. Furthermore, the concurrent administration of vegetable oil (1/2 cup) has shown to increase the bioavailability of the FDA-approved ponazuril product up to 15% (M. Furr, unpublished observations). A loading dose for the FDA-approved diclazuril product is not required, and use of vegetable oil does not increase its bioavailability (Hunyadi, unpublished observations). The FDA-approved benzeneacetonitrile compounds exhibited efficacy ranging from 62 to 67% based on a neurologic examination. The drugs used include levamisole (1 mg/kg PO q12h for the first 2 weeks of antiprotozoal treatment and for the first week of each month thereafter), killed *Propionibacterium acnes* (Eqstim™; Neo- gen, Lansing, MI), mycobacterial wall extract (Equimune® IV; Bioniche Animal Health Vetoquinol, Belville, ON, Canada), inactivated parapox virus (Zylexis, Zoetis, Florham Park, NJ), and transfer factor (4Life® Transfer Factor, 4LifeResearch, Sandy, UT). Because no studies have been conducted to evaluate their efficacy in EPM horses, no recommendations can be made.

**Supportive Medical Treatment**

Nonsteroidal anti-inflammatory drugs such as flunixin meglumine are frequently given to moderately or severely affected horses during the first 3–7 days of antiprotozoal treatment and in an attempt to prevent worsening of neurologic deficits during the early antiprotozoal treatment. In the case of horses which are in danger of falling down or exhibit signs of brain involvement, the additional use of a short course of corticosteroids (0.1 mg/kg of dexamethasone once or twice daily) and dimethyl sulfoxide (1 g/kg as a 10% solution IV or by nasogastric tube once or twice daily) may control the inflammatory response and associated clinical signs. Because the damaged CNS is susceptible to oxidant injury, vitamin E (eg, 20 IU/kg daily per os) is often used as an adjunct antioxidant treatment; it remains to be determined experimentally whether this practice is beneficial.

**Biologic Response Modifiers**

Based on the assumption that horses that develop EPM may be immune compromised, immunomodulators have anecdotally been included by some in treatment of the disease. The drugs used include levamisole (1 mg/kg PO q12h for the first 2 weeks of antiprotozoal treatment and for the first week of each month thereafter), killed *Propionibacterium acnes* (Eqstim™; Neogen, Lansing, MI), mycobacterial wall extract (Equimune® IV; Bioniche Animal Health Vetoquinol, Belville, ON, Canada), inactivated parapox virus (Zylexis, Zoetis, Florham Park, NJ), and transfer factor (4Life® Transfer Factor, 4LifeResearch, Sandy, UT). Because no studies have been conducted to evaluate their efficacy in EPM horses, no recommendations can be made.

**Prevention of EPM**

Preventative approaches to EPM can be achieved by decreasing stress along with reducing exposure to scat from opossums. Practical approaches such as not feeding off the ground, providing separate sources of fresh water for horses and preventing wildlife access to horse pastures, paddocks, and stalls may also help reduce the incidence of protozoal infections in horses. Intermittent use of coccidiostatic and coccidiocidal drugs is another approach used to prevent EPM. Two prophylactic studies have looked at the use of ponazuril after an experimental challenge. Treatment at either 2.5 or 5.0 mg/kg PO q24h of ponazuril was administered beginning 7 days before experimental challenge and continued for 28 days. In that study, administration of ponazuril reduced clinical signs and delayed seroconversion. Intermittent ponazuril paste administration at 20 mg/kg PO every 7 days was associated with a significantly decreased intrathecal anti-*S. neurona* antibody response in horses experimentally inoculated with *S. neurona* sporocysts. Collectively, these 2 studies showed that daily or intermittent treatment with ponazuril minimized but did not eliminate infection in horses experimentally infected with *S. neurona*. Recently, pharmacokinetics of daily low-dose diclazuril (0.5 mg/kg PO q24h) given to adult healthy horses were investigated. Diclazuril pellets, given at a...
low-dose, attained plasma and CSF concentrations known to inhibit \textit{S. neurona} and \textit{N. caninum} in cell culture. The daily administration of a low-dose diclazuril pellet topdressing to healthy foals from a farm with a high exposure rate to \textit{S. neurona} significantly reduced the monthly seroprevalence to \textit{S. neurona} when compared to untreated foals.\textsuperscript{122} The authors of that study suggested that the reported difference in temporal seroprevalence between treated and untreated foals was likely because of the successful reduction of \textit{S. neurona} infection in foals receiving a daily low-dose diclazuril. This preventive strategy has the potential to be used in high-risk horses in an attempt to reduce the incidence of EPM, although, future longitudinal studies will be required before establishing a standard protocol.

**Future directions**

While considerable progress has been made as the original EPM consensus statement in 2002, many questions remain unanswered. The highest priority areas identified by the EPM organizing committee include: (a) identifying whether \textit{S. neurona} can establish a persistent but inapparent infection in the horse, (b) elucidating the nature of the immune response in protection and disease, (c) determining how \textit{S. neurona} causes disease and whether organisms need to be present to cause pathologic changes and clinical signs, (d) elucidating whether \textit{S. neurona} parasite genotype influences infection and severity of signs, (e) identifying whether co-infection with other pathogens can be a contributing factor in EPM cases, (f) expanding the fundamental knowledge of \textit{N. hughesi} as a cause of EPM, including identifying the definitive host, determining all modes of transmission and investigating the host-pathogen relationship, including the protective immune response. The Committee urges support for the aforementioned projects as the knowledge gained from these studies will lead to earlier and more accurate diagnosis, preventive approaches and more efficacious treatments.

**Summary**

Based on the currently published information, it is recommended that horses with neurologic signs consistent with EPM, because of \textit{S. neurona} or \textit{N. hughesi}, have a thorough neurologic examination performed. With this information, neurologic deficits can be identified and the lesion(s) localized. Differentials can be developed and appropriate diagnostic testing can be performed to rule in EPM and rule out other diseases. Current recommendations are for serum and CSF testing for \textit{S. neurona}, \textit{N. hughesi}, or both to identify whether intrathecal antibody production is present. Treatment recommendations for EPM include an FDA-approved treatment, as well as supportive care. Duration of treatment is based on resolution of clinical signs. Horses that develop recurrent signs should be reassessed. As more knowledge is elucidated on the virulence of \textit{S. neurona} and \textit{N. hughesi} and the immune phenotype is elicited, more accurate diagnose, more efficacious treatments, and better preventative approaches will be identified.

**Acknowledgments**

Conflict of Interest Declaration: Dr. Morrow works for Equine Diagnostic Solutions, LLC, Lexington, KY, that offers commercial diagnostic testing for \textit{S. neurona} and \textit{N. hughesi}. Dr. Pusterla works for the William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California at Davis that offers commercial testing for \textit{S. neurona} and \textit{N. hughesi}.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

**References**

1. Rooney JR, Prickett ME, Delaney FM, et al. Focal myelitisencephalitis in horses. Cornell Vet 1970;60:494–501.
2. Prickett ME. Equine spinal ataxia. In: 14th Annual Convention of the American Association of Equine Practitioners, Philadelphia, PA 1968;147–148.
3. Cusick PK, Sells DM, Hamilton DP, et al. Toxoplasmosis in two horses. J Am Vet Med Assoc 1974;164:77–80.
4. Beech J, Dodd DC. Toxoplasma-like encephalomyelitis in the horse. Vet Pathol 1974;11:87–96.
5. Mayhew IG, De Lahunta A, Whitlock RH, et al. Equine protozoal myeloencephalitis. Proe Annu Conv Am Assoc Equine Pract 1977;22d:107–114.
6. Dubey JP, Davis SW, Speer CA, et al. \textit{Sarcocystis neurona} n. sp. (Protozoa: Apicomplexa), the etiologic agent of equine protozoal myeloencephalitis. J Parasitol 1991;77:212–218.
7. Cheadle MA, Lindsay DS, Rowe S, et al. Prevalence of antibodies to Neospora sp. in horses from Alabama and characterisation of an isolate recovered from a naturally infected horse [corrected]. Int J Parasitol 1999;29:1357–1543.
8. Dubey JP, Liddell S, Mattson D, et al. Characterization of the Oregon isolate of Neospora hughesi from a horse. J Parasitol 2001;87:345–353.
9. Hamir AN, Tornquist SI, Gerros TC, et al. Neospora caninum-associated equine protozoal myeloencephalitis. Vet Parasitol 1998;79:269–274.
10. Marsh AE, Barr BC, Madigan J, et al. Neosporosis as a cause of equine protozoal myeloencephalitis. J Am Vet Med Assoc 1996;209:1907–1913.
11. Lindsay DS, Steinberg H, Dubielzig RR, et al. Central nervous system neosporosis in a foal. J Vet Diagn Invest 1996;8:507–510.
12. Fenger CK, Granstrom DE, Langemeier JL, et al. Identification of opossums (\textit{Didelphis virginiana}) as the putative definitive host of \textit{Sarcocystis neurona}. J Parasitol 1995;81:916–919.
13. Dubey JP, Lindsay DS, Kerber CE, et al. First isolation of \textit{Sarcocystis neurona} from the South American opossum, \textit{Didelphis albiventris}, from Brazil. Vet Parasitol 2001;95:295–304.
14. Cheadle MA, Yowell CA, Sellon DC, et al. The striped skunk (\textit{Mephitis mephitis}) is an intermediate host for \textit{Sarcocystis neurona}. Int J Parasitol 2001;31:843–849.
15. Dubey JP, Saville WJ, Staneck JF, et al. \textit{Sarcocystis neurona} infections in raccoons (\textit{Procyon lotor}): evidence for natural infection with sarcocystis, transmission of infection to opossums (\textit{Didel-
phus virginiana), and experimental induction of neurologic disease in raccoons. Vet Parasitol 2001;100:117–129.
16. Chedee MA, Tanhauser SM, Dame JB, et al. The nine-banded armadillo (Dasypus novemcinctus) is an intermediate host for Sarcocystis neurona. Int J Parasitol 2001;31:330–335.
17. Dubey JP, Saville WJ, Lindsay DS, et al. Completion of the life cycle of Sarcocystis neurona. J Parasitol 2000;86:1276–1280.
18. Dubey JP. Prevalence of Sarcocystis species sporocysts in wild-caught opossums (Didelphis virginiana). J Parasitol 2000;86:705–710.
19. Mullaney T, Murphy AJ, Kuipel M, et al. Evidence to support horses as natural intermediate hosts for Sarcocystis neurona. Vet Parasitol 2005;133:27–36.
20. Pivoto FL, de Macedo AG Jr, da Silva MV, et al. Serological status of mares in parturition and the levels of antibodies (IgG) against protozoan family Sarcocystidiae from their pre colostral foals. Vet Parasitol 2014;199:107–111.
21. Pusterla N, Mackie S, Packham A, et al. Serological investigation of transplacental infection with Neospora hughesi and Sarcocystis neurona in broodmares. Vet J 2014;202:649–650.
22. Ellison SP, Greiner E, Brown KK, et al. Experimental infection of horses with culture-derived Sarcocystis neurona merzoites as a model for equine protozoal myeloencephalitis. Int J Appl Res Vet Med 2002;4:79–89.
23. Lindsay DS, Mitchell SM, Yang J, et al. Penetration of equine leukocytes by merzoites of Sarcocystis neurona. Vet Parasitol 2006;138:371–376.
24. Speer CA, Dubey JP, Mattson DE. Comparative developmental and merzoite production of two isolates of Sarcocystis neurona and Sarcocystis falciparum in cultured cells. J Parasitol 2000;86:25–32.
25. Lewis S, Ellison S, Duscano J, et al. Effects of experimental Sarcocystis neurona-induced infection on immunity in an equine model. J Vet Med 2014; doi: 10.1155/2014/239495 (16 pages).
26. McAllister MM, Dubey JP, Lindsay DS, et al. Dogs are definitive hosts of Neospora caninum. Int J Parasitol 1998;28:1473–1478.
27. Antonello AM, Pivoto FL, Camillo G, et al. The importance of vertical transmission of Neospora sp. in naturally infected horses. Vet Parasitol 2012;187:367–370.
28. Pusterla N, Conrad PA, Packham AE, et al. Endogenous transplacental transmission of Neospora hughesi in naturally infected horses. J Parasitol 2011;97:281–285.
29. Dubey JP. Migration and development of Sarcocystis neurona in tissues of interferon gamma knockout mice fed sporocysts from a naturally infected opossum. Vet Parasitol 2001;95:341–351.
30. Witonsky SG, Gogal RM Jr, Duncan RB, et al. Immunopathologic effects associated with Sarcocystis neurona-infected interferon-gamma knockout mice. J Parasitol 2003;89:932–940.
31. Witonsky SG, Gogal RM Jr, Duncan RB, et al. Protective immune response to experimental infection with Sarcocystis neurona in 5BL/6 mice. J Parasitol 2003;89:924–931.
32. Witonsky SG, Gogal RM Jr, Duncan RB, et al. Prevention of meningitis/encephalomyelitis due to Sarcocystis neurona infection in mice is mediated by CD8 cells. Int J Parasitol 2005;35:113–123.
33. Furr M, Pontzer C. Transforming growth factor beta concentrations and interferon gamma responses in cerebrospinal fluid of horses with equine protozoal myeloencephalitis. Equine Vet J 2000;33:721–725.
34. Tornquist SJ, Boeder LJ, Mattson DE, et al. Lymphocyte responses and immunophenotypes in horses with Sarcocystis neurona infection. Equine Vet J 2000;33:726–729.
35. Yang J, Ellison S, Gogal R, et al. Immune response to Sarcocystis neurona infection in naturally infected horses with equine protozoal myeloencephalitis. Vet Parasitol 2006;138:200–210.
36. Saville WJ, Morley PS, Reed SM, et al. Evaluation of risk factors associated with clinical improvement and survival of horses with equine protozoal myeloencephalitis. J Am Vet Med Assoc 2000;217:1181–1185.
37. Saville WJ, Stich RW, Reed SM, et al. Utilization of stress in the development of an equine model for equine protozoal myeloencephalitis. Vet Parasitol 2001;95:211–222.
38. Sofaly CD, Reed SM, Gordon JC, et al. Experimental induction of equine protozoal myeloencephalitis (EPM) in the horse: effect of Sarcocystis neurona sporocyst inoculation dose on the development of clinical neurologic disease. J Parasitol 2002;88:1164–1170.
39. Cutler TJ, MacKay RJ, Ginn PE, et al. Immunoconversion against Sarcocystis neurona in normal and dexamethasone-treated horses challenged with S. neurona sporocysts. Vet Parasitol 2001;95:197–210.
40. Saville WJ, Sofaly CD, Reed SM, et al. An equine protozoal myeloencephalitis challenge model testing a second transport after inoculation with Sarcocystis neurona sporocysts. J Parasitol 2004;90:1406–1410.
41. Asmundsson IM, Dubey JP, Rosenthal BM. A genetically diverse but distinct North American population of Sarcocystis neurona includes an overrepresented clone described by 12 microsatellite alleles. Infect Genet Evol 2006;6:352–360.
42. Elsheikha HM, Schott HC 2nd, Mansfield LS. Genetic variation among isolates of Sarcocystis neurona, the agent of protozoal myeloencephalitis, as revealed by amplified fragment length polymorphism markers. Infect Immun 2006;74:3448–3454.
43. Howe DK, Gaji RY, Marsh AE, et al. Strains of Sarcocystis neurona exhibit differences in their surface antigens, including the absence of the major surface antigen SnsAG1. Int J Parasitol 2008;38:623–631.
44. Wendte JM, Miller MA, Lambourn DM, et al. Self-mating in the definitive host potentiates clonal outbreaks of the apicomplexan parasites Sarcocystis neurona and Toxoplasma gondii. PLoS Genet 2010;6:e1001261.
45. Fayer R, Mayhew IG, Baird JD, et al. Epidemiology of equine protozoal myeloencephalitis in North America based on histologically confirmed cases. J Vet Intern Med 1990;4:54–57.
46. Boy MG, Galligan DT, Divers TJ. Protozoal encephalomyelitis in horses: 82 cases (1972-1986). J Am Vet Med Assoc 1990;196:632–634.
47. Benz BG, Granstrom DE, Stamper S. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in a county of southeastern Pennsylvania. J Am Vet Med Assoc 1997;210:517–518.
48. Benz BG, Ealey KA, Morrow J, et al. Seroprevalence of antibodies to Sarcocystis neurona in equids residing in Oklahoma. J Vet Diag Invest 2003;15:597–600.
49. Blythe LL, Granstrom DE, Hansen DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Oregon. J Am Vet Med Assoc 1997;210:525–527.
50. Saville WJ, Reed SM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Ohio. J Am Vet Med Assoc 1997;210:519–524.
51. Tillotson K, McCue PM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in northern Colorado. J Equine Vet Sci 1999;19:122–126.
52. Dubey JP, Kerber CE, Granstrom DE. Serologic prevalence of Sarcocystis neurona, Toxoplasma gondii, and Neospora caninum in horses in Brazil. J Am Vet Med Assoc 1999;215:970–972.
53. Dubey JP, Venturini MC, Venturini L, et al. Seroprevalence of antibodies to Sarcocystis neurona, Toxoplasma gondii and Neospora caninum in horses from Argentina. Vet Parasitol 1999;86:59–62.
54. Bartova E, Sedlak K, Syrova M, et al. Neospora spp. and Toxoplasma gondii antibodies in horses in the Czech Republic. Parasit Res 2010;107:783–785.
55. Dubey JP, Mitchell SM, Morrow JK, et al. Prevalence of antibodies to Neospora caninum, Sarcocystis neurona, and Toxoplasma gondii in wild horses from central Wyoming. J Parasitol 2003;89:716–720.

56. Pitel PH, Pronost S, Romand S, et al. Prevalence of antibodies to Neospora caninum in horses in France. Equine Vet J 2001;33:205–207.

57. Vardeleon D, Marsh AE, Thorne JG, et al. Prevalence of Neospora hughesi and Sarcocystis neurona antibodies in horses from various geographical locations. Vet Parasitol 2001;95:273–282.

58. Villalobos EM, Furman KE, Lara Mdo C, et al. Detection of Neospora sp. antibodies in cart horses from urban areas of Curitiba, Southern Brazil. Rev Bras Parasitol Vet 2012;21:68–70.

59. Dangoudibiyam S, Oliveira JB, Viquez C, et al. Detection of antibodies against Sarcocystis neurona, Neospora spp., and Toxoplasma gondii in horses from Costa Rica. J Parasitol 2011;97:522–524.

60. Gupta GD, Lakritz J, Kim JH, et al. Seroprevalence of Neospora, Toxoplasma gondii and Sarcocystis neurona antibodies in horses from Jeju island, South Korea. Vet Parasitol 2002;106:193–201.

61. Hoane JS, Gennari SM, Dubey JP, et al. Prevalence of Sarcocystis neurona and Neospora spp. infection in horses from Brazil based on presence of serum antibodies to parasite surface antigen. Vet Parasitol 2006;136:155–159.

62. Hoane JS, Yeargan MR, Stamper S, et al. Recombinant NHsAG1 ELISA: a sensitive and specific assay for detecting antibodies against Neospora hughesi in equine serum. J Parasitol 2005;91:446–452.

63. NAHMS. Equine Protozoal Myeloencephalitis (EPM) in the U.S. In: USDA:APHIS:VS, ed. Centers for Epidemiology and Animal Health. Fort Collins, Colorado: NAHMS; 2001:1–46.

64. MacKay RJ, Davis SW, Dubey JP. Equine protozoal myeloencephalitis. Compend Cont Educ Pract Vet 1992;14:1359–1367.

65. Fenger CK, Granstrom DE, Langemeier JL, et al. Epizootic of equine protozoal myeloencephalitis on a farm. J Am Vet Med Assoc 1997;210:923–927.

66. Granstrom DE, Alvarez O Jr, Dubey JP, et al. Equine protozoal myelitis in Panamanian horses and isolation of Sarcocystis neurona. J Parasitol 1992;78:909–912.

67. Saville WJ, Reed SM, Morley PS, et al. Analysis of risk factors for the development of equine protozoal myeloencephalitis in horses. J Am Vet Med Assoc 2000;217:1174–1180.

68. Dunigan CE, Oglesbee MJ, Pedell M, et al. Seizure activity associated with equine Protozoal Myeloencephalitis. Prog Vet Neurrol 1995;6:50–54.

69. Reed SM, Granstrom DE. Equine protozoal eencephalomyelitis. In: 13th Annual Veterinary Medical Forum of the American College of Veterinary Internal Medicine 1993;591–592.

70. Hamir AN, Moser G, Galligan DT, et al. Immunohistochemical study to demonstrate Sarcocystis neurona in equine protozoal myeloencephalitis. J Vet Diagn Invest 1993;5:418–422.

71. Johnson AL, Morrow JK, Sweeney RW. Indirect fluorescent antibody test and surface antigen ELISAs for antemortem diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med 2013;27:596–599.

72. Reed SM, Howe DK, Morrow JK, et al. Accurate antemortem diagnosis of equine protozoal myeloencephalitis (EPM) based on detecting intrathecal antibodies against Sarcocystis neurona using the SnSAG2 and SnSAG4/3 ELISAs. J Vet Intern Med 2013;27:1193–1200.

73. Furr M. Antigen-specific antibodies in cerebrospinal fluid after intramuscular injection of ovalbumin in horses. J Vet Intern Med 2002;16:588–592.

74. Finno CJ, Packham AE, David Wilson W, et al. Effects of blood contamination of cerebrospinal fluid on results of indirect fluorescent antibody tests for detection of antibodies against Sarcocystis neurona and Neospora hughesi. J Vet Diagn Invest 2007;19:286–289.

75. Furr M, Howe D, Reed S, et al. Antibody coefficients for the diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med 2011;25:138–142.

76. Miller MM, Sweeney CR, Russell GE, et al. Effects of blood contamination of cerebrospinal fluid on western blot analysis for detection of antibodies against Sarcocystis neurona and on albumin quotient and immunoglobulin G index in horses. J Vet Med Assoc 1999;215:67–71.

77. Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology 1995;45:1663–1670.

78. Dorta-Contreras AJ, Reiber H. Intrathecal synthesis of immunoglobulins in eosinophilic meningoencephalitis due to Angiostrongylus cantonensis. Clin Diagn Lab Immunol 1998;5:452–455.

79. Lejon V, Reiber H, Legros D, et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003;187:1475–1483.

80. Contini C, Fainardi E, Cultrera R, et al. Advanced laboratory techniques for diagnosing Toxoplasma gondii encephalitis in AIDS patients: significance of intrathecal production and comparison with PCR and ECL-western blotting. J Neuroimmunol 1998;92:29–37.

81. Potasman I, Resnick L, Luft BJ, et al. Intrathecal production of antibodies against Toxoplasma gondii in patients with toxoplasemic encephalitis and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:49–51.

82. Daft BM, Barr BC, Gardner IA, et al. Sensitivity and specificity of western blot testing of cerebrospinal fluid and serum for diagnosis of equine protozoal myeloencephalitis in horses with and without neurologic abnormalities. J Am Vet Med Assoc 2002;221:1007–1013.

83. Duarte PC, Daft BM, Conrad PA, et al. Comparison of serum indirect fluorescent antibody test with two Western blot tests for the diagnosis of equine protozoal myeloencephalitis. J Vet Diagn Invest 2003;15:8–13.

84. Duarte PC, Daft BM, Conrad PA, et al. Evaluation and comparison of an indirect fluorescent antibody test for detection of antibodies to Sarcocystis neurona, using serum and cerebrospinal fluid of naturally and experimentally infected, and vaccinated horses. J Parasitol 2000;86:1034–1037.

85. Duarte PC, Ebel ED, Traub-Dargatz J, et al. Indirect fluorescent antibody testing of cerebrospinal fluid for diagnosis of equine protozoal myeloencephalitis. Am J Vet Res 2006;67:869–876.

86. Ellison SP, Kennedy TJ, Brown KK. Development of an ELISA to detect antibodies to rSAG1 in the horse. Int J App Res Vet Med 2003;1:318–327.

87. Granstrom DE, Dubey JP, Davis SW, et al. Equine protozoal myeloencephalitis: antigen analysis of cultured Sarcocystis neurona merozoites. J Vet Diagn Invest 1993;5:88–90.

88. Hoane JS, Morrow JK, Saville WJ, et al. Enzyme-linked immunosorbent assays for the detection of equine antibodies specific to Sarcocystis neurona surface antigens. Clin Diagn Lab Immunol 2005;12:1050–1056.

89. Johnson AL, Burton AJ, Sweeney RW. Utility of 2 immunological tests for antemortem diagnosis of equine protozoal myeloencephalitis (Sarcocystis neurona Infection) in naturally occurring cases. J Vet Intern Med 2010;24:1184–1189.

90. Rossano MG, Mansfield LS, Kaneene JB, et al. Improvement of western blot test specificity for detecting equine serum antibodies to Sarcocystis neurona. J Vet Diagn Invest 2000;12:28–32.
91. Yeargan MR, Howe DK. Improved detection of equine antibodies against *Sarcocystis neurona* using polyclonal ELISAs based on the parasite SnSAG surface antigens. Vet Parasitol 2011;176:16–22.

92. Ellison SP, Lindsay DS. Decoquinate combined with leva-misole reduce the clinical signs and Serum SAG 1, 5, 6 antibodies in horses with suspected equine protozoal myeloencephalitis. Int J Appl Res Vet Med 2012;10:1–7.

93. Granstrom D. Equine protozoal myeloencephalitis: Parasite biology, experimental disease, and laboratory diagnosis. In: International Equine Neurology Conference, Ithaca, NY 1997.

94. Ellison SP, Omar-Opene AL, Yowell CA, et al. Molecular characterisation of a major 29 kDa surface antigen of *Sarcocystis neurona*. Int J Parasitol 2002;32:217–225.

95. Howe DK, Gaji Ry, Mroz-Barrett M, et al. *Sarcocystis neurona* merozoites express a family of immunogenic surface antigens that are orthologues of the *Toxoplasma gondii* surface antigens (SAGs) and SAG-related sequences. Infect Immun 2005;73:1023–1033.

96. Marsh AE, Howe DK, Wang G, et al. Differentiation of *Neospora hughesi* from *Neospora caninum* based on their immunodominant surface antigen, SAG1 and SRS2. Int J Parasitol 1999;29:1575–1582.

97. Reed SM, Howe DK, Yeargan MR, et al. New quantitative assays for the differential diagnosis of equine protozoal myeloencephalitis (EPM). In: ACVIM Forum 2010.

98. Renier AC, Morrow JK, Graves A, et al. Diagnosis of equine protozoal myeloencephalitis using indirect fluorescent antibody testing and enzyme-linked immunosorbent assay titer ratios for Sarcocystis neurona and Neospora hughesi. In: ACVIM Forum, EPM SIG 2012.

99. Saville WJ. Comparison of diagnostic tests for EPM run on blinded sera at four different laboratories. In: ACVIM Forum, EPM SIG 2007.

100. Packham AE, Conrad PA, Wilson WD, et al. Qualitative evaluation of selective tests for detection of *Neospora hughesi* antibodies in serum and cerebrospinal fluid of experimentally infected horses. J Parasitol 2002;88:1239–1246.

101. Bogan JA, Galbraith A, Baxter P, et al. Effect of feeding on the fate of orally administered phenylbutazone, trimethoprim and sulfadiazine in the horse. Vet Rec 1984;115:599–600.

102. Clarke CR, MacAllister CG, Burrows GE, et al. Pharmacokinetics, penetration into cerebrospinal fluid, and hematologic effects after multiple oral administrations of pyrimethamine to horses. Am J Vet Res 1992;53:2296–2299.

103. Cavallito JC, Nichol CA, Breckman WD Jr, et al. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab Dispos 1978;6:329–337.

104. Green SL, Mayhew IG, Brown MP, et al. Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment. Can J Vet Res 1990;54:215–222.

105. Reed S, Saville WJ. Equine Protozoal Myeloencephalitis. In: 42nd Annual Meeting of the American Association of Equine Practitioners 1996;75–79.

106. Welsch BB. Treatment of equine protozoal myeloencephalitis. Comp Cont Ed Pract Vet 1991;13:1599–1602.

107. Chung MK, Han SS, Roh JK. Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats. Reprod Toxicol 1993;7:463–468.

108. Toribio RE, Bain FT, Mard DR, et al. Congenital defects in newborn foals of mares treated for equine protozoal myeloencephalitis during pregnancy. J Am Vet Med Assoc 1998;212:697–701.

109. Castles TR, Kintner LD, Lee CC. The effects of folic or folinic acid on the toxicity of pyrimethamine in dogs. Toxicol Appl Pharmacol 1971;20:447–459.

110. Hackstein JH, Mackenstedt U, Mehlhorn H, et al. Parasitic apicomplexans harbor a chlorophyll a-D1 complex, the potential target for therapeutic triazines. Parasitol Res 1995;81:207–216.

111. Lindsay DS, Dubey JP. Determination of the activity of diclazuril against *Sarcocystis neurona* and *Sarcocystis falcata* in cell cultures. J Parasitol 2000;86:164–166.

112. Lindsay DS, Dubey JP, Kennedy TJ. Determination of the activity of ponazuril against *Sarcocystis neurona* in cell cultures. Vet Parasitol 2000;92:165–169.

113. Lindsay DS, Rippey NS, Cole RA, et al. Examination of the activities of 43 chemotherapeutic agents against *Neospora caninum* tachyzoites in cultured cells. Am J Vet Res 1994;55:976–981.

114. Dirikolu L, Lehner F, Nattrass C, et al. Diclazuril in the horse: its identification and detection and preliminary pharmacokinetics. J Vet Pharmacol Ther 1999;22:374–379.

115. Furr M, Kennedy T. Cerebrospinal fluid and serum concentrations of ponazuril in horses. Vet Ther 2001;2:232–237.

116. Hunyadi L, Papich MG, Pusterla N. Pharmacokinetics of a low dose and FDA-labeled dose of diclazuril administered orally as a pellets topdressing in adult horses. J Vet Pharmacol Ther 2015;38:243–248.

117. Reed SM, Wendel M, King S, et al. Pharmacokinetics of Ponazuril in Horses. In: 58th Annual Convention of the American Association of Equine Practitioners, Anaheim, CA 2012:572.

118. Furr M, Kennedy T, MacKay R, et al. Efficacy of ponazuril 15% oral paste as a treatment for equine protozoal myeloencephalitis. Vet Ther 2001;2:215–222.

119. Benz BG, Dirikolu L, Carter WG, et al. Equine protozoal myeloencephalitis (EPM): a clinical report. Equine Vet Educ 2000;16:258–263.

120. Furr M, McKenzie H, Saville WJ, et al. Prophylactic administration of ponazuril reduces clinical signs and delays seroconversion in horses challenged with *Sarcocystis neurona*. J Parasitol 2006;92:637–643.

121. Mackay RJ, Tanhauser ST, Gillis KD, et al. Effect of intermittent oral administration of ponazuril on experimental *Sarcocystis neurona* infection of horses. Am J Vet Res 2008;69:396–402.

122. Pusterla N, Packham A, Mackie S, et al. Daily feeding of diclazuril top dress pellets in foals reduces seroconversion to *Sarcocystis neurona*. Vet J 2015;206:236–238. 10.1016/j.tvjl.2015.07.018